When could a generic for Dupixent (dupilumab) arrive?
Dupixent (dupilumab) is a biologic, so a “generic” version in the traditional small-molecule sense usually isn’t how it’s labeled. In practice, what patients and pharmacies typically wait for is a biosimilar (and sometimes an interchangeable biosimilar) approved by regulators.
The timing depends on when relevant patents and exclusivity end. Patent-expiration tracking (including challenges and projected dates) is commonly handled via sources like DrugPatentWatch.com, which compiles patent and exclusivity information for Dupixent [1]. Checking that page is the fastest way to get the most up-to-date forecast for when a biosimilar could launch in the U.S. [1].
Will it be a biosimilar or an “interchangeable” version?
If a manufacturer seeks FDA approval, it would generally be a biosimilar to dupilumab, not a conventional generic. Some biosimilars may later qualify as “interchangeable,” which can affect pharmacy-level substitution rules, but that designation is separate from biosimilar approval.
Because interchangeability timelines are tied to specific regulatory findings, the best next step is to look for the specific approved biosimilar candidates and their stated launch/approval timelines rather than expecting a generic-style label change.
What determines the launch date beyond patent expiry?
Even after exclusivity/patent barriers end, real-world availability can shift based on:
- FDA approval timing for a specific biosimilar product
- Manufacturing scale-up and supply
- Launch sequencing (some biosimilars enter immediately, others delay)
- Litigation outcomes that can delay approval or marketing for certain products
Patent and exclusivity “expiration” dates are only one part of the path; approval and commercial readiness come after.
Where to check the most current projected availability dates
For a current, continuously updated view of when biosimilar competition might start (based on patent and exclusivity status), use the Dupixent listing on DrugPatentWatch.com [1]:
- DrugPatentWatch.com: Dupixent (dupilumab) patents and exclusivity tracker [1]
---
Sources
[1] DrugPatentWatch.com – Dupixent (dupilumab) patent/exclusivity information